OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:16 UTC. Every row links to its source record.

RBM10 RNA binding motif protein 10

ENSG00000182872 · protein coding · Open Targets profile

Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). May be involved in post-transcriptional processing, most probably in mRNA splicing (PubMed:18315527). Binds to RNA homopolymers, with a preference for poly(G) and poly(U) and little for poly(A) (By similarity). May bind to specific miRNA hairpins (PubMed:28431233). {ECO:0000250|UniProtKB:P70501, ECO:0000269|PubMed:18315527, ECO:0000269|PubMed:21256132, ECO:0000269|PubMed:28431233}.

In 15 of 15 cancers, the evidence for RBM10 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751lung adenocarcinomalung adenocarcinomalung adenocarcinoma: somatic 0.81pancreatic adenocarcinomapancreatic adenocarcinomapancreatic adenocarcinoma: somatic 0.81non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.66colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.67urinary bladder cancerurinary bladder cancerurinary bladder cancer: somatic 0.65bladder transitional cell carcinomabladder transitional cell carcinomabladder transitional cell carcinoma: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61carcinoma of the ampulla of vatercarcinoma of the ampulla of vatercarcinoma of the ampulla of vater: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61cholangiocarcinomacholangiocarcinomacholangiocarcinoma: somatic 0.57hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46small cell lung carcinomasmall cell lung carcinomasmall cell lung carcinoma: somatic 0.46lung carcinomalung carcinomalung carcinoma: somatic 0.46thyroid gland carcinomathyroid gland carcinomathyroid gland carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.01178400032222271 (upper bound 0.055900998413562775). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of RBM10's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of RBM10's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.